Literature DB >> 11279005

The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.

M E Baldwin1, B Catimel, E C Nice, S Roufail, N E Hall, K L Stenvers, M J Karkkainen, K Alitalo, S A Stacker, M G Achen.   

Abstract

Human vascular endothelial growth factor-D (VEGF-D) binds and activates VEGFR-2 and VEGFR-3, receptors expressed on vascular and lymphatic endothelial cells. As VEGFR-2 signals for angiogenesis and VEGFR-3 is thought to signal for lymphangiogenesis, it was proposed that VEGF-D stimulates growth of blood vessels and lymphatic vessels into regions of embryos and tumors. Here we report the unexpected finding that mouse VEGF-D fails to bind mouse VEGFR-2 but binds and cross-links VEGFR-3 as demonstrated by biosensor analysis with immobilized receptor domains and bioassays of VEGFR-2 and VEGFR-3 cross-linking. Mutation of amino acids in mouse VEGF-D to those in the human homologue indicated that residues important for the VEGFR-2 interaction are clustered at, or are near, the predicted receptor-binding surface. Coordinated expression of VEGF-D and VEGFR-3 in mouse embryos was detected in the developing skin where the VEGF-D gene was expressed in a layer of cells beneath the developing epidermis and VEGFR-3 was localized on a network of vessels immediately beneath the VEGF-D-positive cells. This suggests that VEGF-D and VEGFR-3 may play a role in establishing vessels of the skin by a paracrine mechanism. Our study of receptor specificity suggests that VEGF-D may have different biological functions in mouse and man.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11279005     DOI: 10.1074/jbc.M100097200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis.

Authors:  Jörg Wilting; Bodo Christ; Li Yuan; Anne Eichmann
Journal:  Naturwissenschaften       Date:  2003-09-17

2.  When it comes to blocking lymphatics, it is all a question of time.

Authors:  M Luisa Iruela-Arispe
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Wound angiogenesis as a function of tissue oxygen tension: a mathematical model.

Authors:  Richard C Schugart; Avner Friedman; Rui Zhao; Chandan K Sen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

Review 4.  Receptor tyrosine kinase-mediated angiogenesis.

Authors:  Michael Jeltsch; Veli-Matti Leppänen; Pipsa Saharinen; Kari Alitalo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

5.  CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.

Authors:  J Dawn Waters; Carlos Sanchez; Ayguen Sahin; Diahnn Futalan; David D Gonda; Justin K Scheer; Johnny Akers; Kamalakannan Palanichamy; Peter Waterman; Arnab Chakravarti; Ralph Weissleder; Brent Morse; Nick Marsh; Eric Furfine; Clark C Chen; Irvith Carvajal; Bob S Carter
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

Review 6.  Proposed new lymphology combined with lymphatic physiology, innate immunology, and oncology.

Authors:  Toshio Ohhashi; Yoshiko Kawai
Journal:  J Physiol Sci       Date:  2014-11-07       Impact factor: 2.781

7.  Vascular endothelial growth factor D is dispensable for development of the lymphatic system.

Authors:  Megan E Baldwin; Michael M Halford; Sally Roufail; Richard A Williams; Margaret L Hibbs; Dianne Grail; Hajime Kubo; Steven A Stacker; Marc G Achen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle.

Authors:  Andrey Anisimov; Annamari Alitalo; Petra Korpisalo; Jarkko Soronen; Seppo Kaijalainen; Veli-Matti Leppänen; Michael Jeltsch; Seppo Ylä-Herttuala; Kari Alitalo
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

9.  VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts.

Authors:  Ingrid Nilsson; Fuad Bahram; Xiujuan Li; Laura Gualandi; Sina Koch; Malin Jarvius; Ola Söderberg; Andrey Anisimov; Ivana Kholová; Bronislaw Pytowski; Megan Baldwin; Seppo Ylä-Herttuala; Kari Alitalo; Johan Kreuger; Lena Claesson-Welsh
Journal:  EMBO J       Date:  2010-03-11       Impact factor: 11.598

10.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.